Most Recent
Cipla is opposing the extension of Novo Nordisk’s patent for its Victoza weight loss and diabetes drug, arguing extensions can only be granted for active ingredients and not entire formulations.
The National Anti-Corruption Commission will reconsider investigating six people involved in the Robodebt scheme after a report found commissioner Paul Brereton SC should have done more to remove himself from the decision.
The judge overseeing a $180.4 million settlement in a stolen wages class action has railed against Shine Lawyers' $10 million bill for the costs of registration, saying “something has gone seriously wrong”.
As Mineral Resources and WiseTech face shareholder glare over accusations levelled at their billionaire bosses, it is Herbert Smith Freehills that their embattled boards have turned to.
Medibank is seeking to shield from a shareholder class action an "irrelevant" post-incident report by Deloitte into its massive October 2022 data breach.
Investment manager Salter Brothers has sued XL Insurance, saying it has “unreasonably delayed” covering the costs of defending a former client’s lawsuit alleging misleading conduct.
United Petroleum will not face cross-claims by franchisees, with a judge calling the bid “a very colourable application” to create overlap with a class action in the Supreme Court.
AstraZeneca has brought court proceedings to block Australian drug maker Pharmacor from making a generic version of its heart attack drug Brilinta.
ASIC has won its case against insurer HCF Life over a pre-existing condition term that was likely to mislead the public, but failed to convince the court that it was an unfair contract term.
Santos’ plan to reach net zero greenhouse gas emissions by 2040 was “little more than a series of speculations”, a shareholder group has said on the first day of trial in a landmark greenwashing case.